Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 23008132)

1.

Interleukin-28B polymorphism in hepatitis C and liver transplantation.

Duarte-Rojo A, Deneke MG, Charlton MR.

Liver Transpl. 2013 Jan;19(1):49-58. doi: 10.1002/lt.23554.

2.

CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant.

Firpi RJ, Dong H, Clark VC, Soldevila-Pico C, Morelli G, Cabrera R, Norkina O, Shuster JJ, Nelson DR, Liu C.

Liver Int. 2013 Jan;33(1):72-8. doi: 10.1111/liv.12013. Epub 2012 Oct 29.

3.

The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables.

Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt KD, Heimbach JK, McHutchison JG, Poterucha JJ, Vargas-Vorackova F, Charlton MR.

Transplantation. 2012 Jul 27;94(2):197-203. doi: 10.1097/TP.0b013e3182547551.

PMID:
22766768
4.

Recipient interleukin-28B Rs12979860 C/T polymorphism and acute cellular rejection after liver transplantation: role of the calcineurin inhibitor used.

Bitetto D, Fabris C, Falleti E, Fornasiere E, Avellini C, Cmet S, Cussigh A, Fontanini E, Pirisi M, Corradini SG, Merli M, Molinaro A, Toniutto P.

Transplantation. 2012 May 27;93(10):1038-44. doi: 10.1097/TP.0b013e31824df7f3.

PMID:
22495472
5.

Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation.

Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, Neuhaus R, Neuhaus P, Neumann UP, Bahra M.

Liver Transpl. 2011 Mar;17(3):289-98. doi: 10.1002/lt.22235.

6.

Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation.

Graziadei IW, Zoller HM, Schloegl A, Nachbaur K, Pfeiffer KP, Mark W, Mikuz G, Pratschke J, Margreiter R, Vogel W.

Liver Transpl. 2012 Jun;18(6):671-9. doi: 10.1002/lt.23402.

7.

Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment.

Ackefors M, Nyström J, Wernerson A, Gjertsen H, Sönnerborg A, Weiland O.

J Viral Hepat. 2013 Nov;20(11):770-8. doi: 10.1111/jvh.12099. Epub 2013 Apr 23.

PMID:
24168256
8.

Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection.

Osaki R, Nishimura T, Shioya M, Takeuchi T, Okumura Y, Nakahara T, Bamba S, Nakajo S, Fujiyama Y, Andoh A.

Mol Med Rep. 2012 Feb;5(2):525-8. doi: 10.3892/mmr.2011.655. Epub 2011 Nov 1.

PMID:
22052088
9.

Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy.

Eurich D, Boas-Knoop S, Bahra M, Neuhaus R, Somasundaram R, Neuhaus P, Neumann U, Seehofer D.

Transplantation. 2012 Mar 27;93(6):644-9. doi: 10.1097/TP.0b013e318244f774.

PMID:
22411462
10.

Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection.

Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, Heimbach JK, Goldstein D, McHutchison J.

Hepatology. 2011 Jan;53(1):317-24. doi: 10.1002/hep.24074.

11.

Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review.

Duarte-Rojo A, Budhraja V, Veldt BJ, Goldstein DD, Watt KD, Heimbach JK, McHutchison JG, Tillman HL, Poterucha JJ, Charlton MR.

Liver Transpl. 2013 Dec;19(12):1311-7. doi: 10.1002/lt.23733. Review.

12.

Factors that predict response of patients with hepatitis C virus infection to boceprevir.

Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators.

Gastroenterology. 2012 Sep;143(3):608-18.e1-5. doi: 10.1053/j.gastro.2012.05.011. Epub 2012 May 21.

PMID:
22626609
13.

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.

Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG.

Gastroenterology. 2010 Sep;139(3):821-7, 827.e1. doi: 10.1053/j.gastro.2010.05.079. Epub 2010 Jun 2.

PMID:
20621700
14.

Association of polymorphisms in interleukin-18 and interleukin-28B with hepatitis B recurrence after liver transplantation in Chinese Han population.

Li Y, Shi Y, Chen J, Cai B, Ying B, Wang L.

Int J Immunogenet. 2012 Aug;39(4):346-52. doi: 10.1111/j.1744-313X.2012.01097.x. Epub 2012 Feb 10.

PMID:
22325058
15.

Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.

Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, Fornasiere E, Pasino M, Ieluzzi D, Cussigh A, Cmet S, Pirisi M, Toniutto P.

Hepatology. 2011 Apr;53(4):1118-26. doi: 10.1002/hep.24201.

PMID:
21480318
16.

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG.

Gastroenterology. 2010 Jul;139(1):120-9.e18. doi: 10.1053/j.gastro.2010.04.013. Epub 2010 Apr 24.

PMID:
20399780
17.

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients.

Sinn DH, Kim YJ, Lee ST, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW.

J Gastroenterol Hepatol. 2011 Sep;26(9):1374-9. doi: 10.1111/j.1440-1746.2011.06744.x.

PMID:
21501223
18.

Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.

Lange CM, Moradpour D, Doehring A, Lehr HA, Müllhaupt B, Bibert S, Bochud PY, Antonino AT, Pascual M, Farnik H, Shi Y, Bechstein WO, Moench C, Hansmann ML, Sarrazin C, Lötsch J, Zeuzem S, Hofmann WP.

J Hepatol. 2011 Aug;55(2):322-7. doi: 10.1016/j.jhep.2010.10.037. Epub 2010 Dec 13.

PMID:
21147186
19.

Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation.

Coto-Llerena M, Pérez-Del-Pulgar S, Crespo G, Carrión JA, Martínez SM, Sánchez-Tapias JM, Martorell J, Navasa M, Forns X.

Am J Transplant. 2011 May;11(5):1051-7. doi: 10.1111/j.1600-6143.2011.03491.x. Epub 2011 Apr 5.

20.

The association of IL28B polymorphism and graft survival in patients with hepatitis C undergoing liver transplantation.

Allam SR, Krüger B, Mehrotra A, Schiano T, Schröppel B, Murphy B.

PLoS One. 2013;8(1):e54854. doi: 10.1371/journal.pone.0054854. Epub 2013 Jan 30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk